Skip to main content
. Author manuscript; available in PMC: 2012 Nov 1.
Published in final edited form as: Nat Rev Immunol. 2012 Apr 20;12(5):325–338. doi: 10.1038/nri3198

Table 1.

Genetic models of T cell-specific deletion of mTOR components and negative regulators.

Target genes Cre types Biochemical defects Thymic phenotypes Peripheral phenotypes Refs
Mtor CD4-Cre Abrogated mTORC1 and mTORC2 activities None Diminished TH1, TH2 and TH17 and spontaneous induced TReg differentiation 6, 30
Rheb CD4-Cre Abrogated mTORC1 activity None Diminished TH1 and TH17 and increased TH2 differentiation 30
Rictor CD4-Cre; dLck-iCre Abrogated mTORC2 activity None Diminished TH2 (both lines) and TH1 (in dLck-iCre) differentiation 30, 77
Pten CD4-Cre; Lck-Cre Increased AKT and mTOR activities Lymphoma; minor defects in development Autoimmune disease 44–47, 49–51
Tsc1 CD4-Cre; Lck-Cre Increased mTORC1 and decreased mTORC2 activities None (CD4-Cre) or minor reduction of cell number (Lck-Cre) Loss of T cell quiescence and survival; diminished antigen-specific response 7–9
Lkb1 CD4-Cre; Lck-Cre Diminished AMPK and increased mTORC1 activities Reduced survival; defective α-selection and positive selection Reduced survival and TCR-induced proliferation; increased metabolism and cytokine production 57–60